Table 1 Number and age-standardised prevalence of people with blindness (<3/60) or MSVI (<6/18 to >/=3/60) due to URE in 7 Super Regions in 2020.
GLOBAL | Central Europe, Eastern Europe, and Central Asia | High income | Latin America and Caribbean | North Africa and Middle East | South Asia | Southeast Asia, East Asia, and Oceania | Sub-Saharan Africa | |
|---|---|---|---|---|---|---|---|---|
Total population 2020 (thousands) | 7,890,000 | 417,000 | 1,090,000 | 602,000 | 632,000 | 1,840,000 | 2,190,000 | 1,110,000 |
Number of people with blindness (thousands) | 3700 (3100–4290) | 29.4 (23.3–36.0) | 80.0 (63.6–97.6) | 218 (180–258) | 190 (156–229) | 1520 (1260–1770) | 1410 (1150–1650) | 254 (212–303) |
Number of Men with blindness (thousands) | 1750 (1480–2020) | 13.7 (10.8–17.1) | 36.9 (29.1–44.8) | 96.1 (78.6–114) | 90.4 (73.6–109) | 728 (606 –847) | 657 (539–769) | 123 (102–146) |
Number of Women with blindness (thousands) | 1950 (1620–2280) | 15.7 (12.4–19.2) | 43.1 (34.6–52.3) | 122 (101–144) | 99.8 (81.8–120) | 789 (658–925) | 750 (616–879) | 132 (110–157) |
Number of people with blindness aged 50+ years (thousands) | 2290 (1790–2800) | 16.8 (12.8–21.1) | 46.1 (35.7–56.9) | 126 (97.5–153) | 84.2 (63.8–103) | 976 (762–1190) | 933 (728–1140) | 111 (84.5–136) |
Number of Men with blindness aged 50+ years (thousands) | 1050 (816–1270) | 7.05 (5.27–8.88) | 21.1 (16.2–26.1) | 53.8 (41.3–65.7) | 39.3 (29.6–48.3) | 459 (358–558) | 415 (325–509) | 52.5 (40.2–65.0) |
Number of Women with blindness aged 50+ years (thousands) | 1250 (975 –1520) | 9.76 (7.35–12.4) | 25.0 (19.3–30.9) | 72.5 (56.4–87.6) | 44.9 (34.1–55.3) | 517 (402–633) | 518 (406–632) | 58.2 (44.3–71.9) |
Age-standardised prevalence of blindness | 0.04% (0.04–0.05) | 0.01% (0.00–0.01) | 0.01% (0.00–0.01) | 0.04% (0.03–0.04) | 0.03% (0.03–0.04) | 0.10% (0.08–0.12) | 0.05% (0.04–0.06) | 0.04% (0.03–0.04) |
Age-standardised prevalence of blindness: Men | 0.04% (0.04–0.05) | 0.01% (0.00–0.01) | 0.01% (0.00–0.01) | 0.03% (0.03–0.04) | 0.03% (0.03–0.04) | 0.10% (0.08–0.11) | 0.05% (0.04–0.06) | 0.04% (0.03–0.05) |
Age-standardised prevalence of blindness: Women | 0.05% (0.04–0.05) | 0.01% (0.00–0.01) | 0.01% (0.00–0.01) | 0.04% (0.03–0.04) | 0.04% (0.03–0.04) | 0.10% (0.09–0.12) | 0.06% (0.05–0.06) | 0.04% (0.03–0.04) |
Age-standardised prevalence of blindness 50+ years | 0.12% (0.10–0.15) | 0.01% (0.01–0.02) | 0.01% (0.01–0.01) | 0.09% (0.07–0.11) | 0.09% (0.07–0.11) | 0.33% (0.26–0.40) | 0.15% (0.12–0.18) | 0.11% (0.09–0.14) |
Age-standardised prevalence of blindness in Men 50+ years | 0.12% (0.09–0.14) | 0.01% (0.01–0.02) | 0.01% (0.01–0.01) | 0.09% (0.07–0.11) | 0.08% (0.06–0.10) | 0.32% (0.25–0.38) | 0.14% (0.11–0.17) | 0.12% (0.09–0.14) |
Age-standardised prevalence of blindness in Women 50+ years | 0.13% (0.10–0.15) | 0.01% (0.01–0.01) | 0.01% (0.01–0.01) | 0.10% (0.08–0.12) | 0.09% (0.07–0.12) | 0.34% (0.27–0.42) | 0.16% (0.12–0.19) | 0.11% (0.09–0.14) |
Percentage of all blindness | 8.60% (7.22–9.99) | 2.07% (1.64–2.54) | 2.66% (2.11–3.24) | 5.96% (4.92–7.04) | 6.15% (5.03–7.40) | 12.71% (10.58–14.82) | 9.34% (7.67–10.94) | 5.00% (4.17–5.96) |
Number of people with MSVI (thousands) | 157,000 (140,000–176,000) | 9660 (8560–10,900) | 17,100 (15,200–18,900) | 14,700 (13,000–16,300) | 12,800 (11,400–14,400) | 53,900 (47,800–60,900) | 39,700 (35,400–44,600) | 9620 (8480–10,900) |
Number of Men with MSVI (thousands) | 73,300 (65,400–81,900) | 3830 (3380–4310) | 8240 (7300–9150) | 6550 (5820–7300) | 6380 (5660–7120) | 25,600 (22,700–28,900) | 18,200 (16,200–20,400) | 4520 (3970–5120) |
Number of Women with MSVI (thousands) | 84,100 (74,900–93,900) | 5830 (5180–6600) | 8850 (7900–9810) | 8140 (7180–9070) | 6460 (5740–7240) | 28,200 (25,000–31,900) | 21,500 (19,200–24,200) | 5100 (4500–5760) |
Number of people with MSVI aged 50+ years (thousands) | 86,100 (74,200–101,000) | 6340 (5400–7480) | 8940 (7680–10,400) | 5780 (4950–6780) | 4680 (3960–5550) | 32,150 (27,500–37,900) | 25,050 (21,500–29,300) | 3210 (2730–3800) |
Number of Men with MSVI aged 50+ years (thousands) | 39,000 (33,600–45,810) | 2270 (1920–2710) | 3720 (3200–4310) | 2610 (2240–3070) | 2280 (1900–2690) | 15,600 (13,300–18,400) | 11,100 (9550–13,100) | 1480 (1260–1750) |
Number of Women with MSVI aged 50+ years (thousands) | 47,100 (40,600–55,200) | 4070 (3470–4780) | 5220 (4490–6010) | 3170 (2720–3710) | 2400 (2030–2840) | 16,600 (14,200–19,500) | 13,900 (12,000–16,200) | 1730 (1470–2050) |
Age-standardised prevalence of MSVI | 1.91% (1.71–2.13) | 1.85% (1.65–2.06) | 1.37% (1.21–1.53) | 2.39% (2.12–2.65) | 2.24% (2.00–2.50) | 3.37% (2.99–3.81) | 1.60% (1.43–1.78) | 1.24% (1.10–1.38) |
Age-standardised prevalence of MSVI: Men | 1.83% (1.63–2.04) | 1.69% (1.50–1.88) | 1.41% (1.25–1.60) | 2.22% (1.97–2.46) | 2.17% (1.93–2.42) | 3.25% (2.89–3.65) | 1.49% (1.33–1.66) | 1.21% (1.08–1.35) |
Age-standardised prevalence of MSVI: Women | 2.00% (1.78–2.23) | 1.98% (1.76–2.22) | 1.31% (1.16–1.47) | 2.56% (2.27–2.86) | 2.32% (2.07–2.59) | 3.51% (3.11–3.97) | 1.70% (1.52–1.90) | 1.27% (1.12–1.42) |
Age-standardised prevalence of MSVI 50+ years | 4.58% (3.96–5.37) | 4.51% (3.85–5.31) | 1.94% (1.67–2.25) | 4.28% (3.68–5.00) | 4.73% (4.02–5.54) | 10.28% (8.82–12.06) | 3.94% (3.39–4.56) | 3.16% (2.73–3.70) |
Age-standardised prevalence of MSVI in Men 50+ years | 4.41% (3.80–5.16) | 3.97% (3.41–4.70) | 1.80% (1.55–2.10) | 4.21% (3.62–4.92) | 4.57% (3.88–5.36) | 10.19% (8.74–11.89) | 3.66% (3.16–4.26) | 3.13% (2.70–3.65) |
Age-standardised prevalence of MSVI in Women 50+ years | 4.75% (4.09–5.56) | 4.89% (4.18–5.76) | 2.05% (1.76–2.38) | 4.35% (3.74–5.09) | 4.88% (4.14–5.72) | 10.40% (8.93–12.18) | 4.19% (3.62–4.87) | 3.19% (2.74–3.74) |
Percentage of all MSVI | 53.39% (47.56–59.51) | 53.69% (47.61–60.63) | 55.00% (49.02–60.95) | 60.00% (53.21–66.69) | 58.76% (52.21–65.72) | 55.99% (49.64–63.32) | 47.84% (42.61–53.69) | 47.06% (41.49–53.29) |
